Evaluating the Younger contest reveals that biological age is not a single metric. Different consumer tests measure distinct signals and lack FDA approval.
In October 2026, MIT Technology Review published an analysis of the Younger contest, a six-month biological-age competition organized by NeuroAge Therapeutics that tracks participants using multiple testing methods.
The primary scientific conclusion drawn from evaluating this setup is that biological age is not a single standardized measurement. Stanford Medicine experts confirm that there is no universally agreed-upon way to measure it, and tests often yield vastly different results because they examine completely separate biological signals. Consequently, improving a score on one specific assessment does not establish that a participant has reversed their overall physiological aging process.
This competition and all evaluated direct-to-consumer aging tests are conducted in humans.
Different clocks propose different biological pathways to measure the aging process. Some clocks examine epigenetic chemical groups on DNA, while alternative approaches analyze circulating blood proteins or lipids. Stanford Medicine notes that DNA-methylation clocks specifically read chemical marks on DNA. However, blood-based epigenetic tests primarily reflect the aging of blood cells and do not directly measure how other internal organs are physically aging.
The Younger contest was organized by neuroscientist and physician Christin Glorioso, who is the founder and CEO of NeuroAge Therapeutics. Rather than relying on a single aging clock, competitors try to improve their overall scores using several different clinical measurements. The contest was set to officially kick off in January, while each competitor's six-month period begins when they record their own baseline measurements. MIT Technology Review reported that roughly 120 people had signed up when the article appeared, and Glorioso expected around 500 total participants.
The competition features two primary leaderboard awards to incentivize participation. One award recognizes the largest gap between chronological and biological age, and another honors the greatest change in biological age over the event. To compete for these titles, participants must purchase entry packages that dictate the specific scope of their biological testing. Specialist coverage reports entry prices of $999 for the standard package and $4,499 for the premium Ultra tier.
In the standard entry described by MIT Technology Review, a dried blood-spot test from TruDiagnostic estimates an overall biological age, a specific pace of aging, and distinct ages for 11 organ systems. This testing protocol includes estimates for critical physiological systems like the heart and brain. Participants also receive a NeuroAge brain-age score, a Harvard-developed face-age estimate based on selfies, and functional physical measures. These functional metrics include baseline tests like grip strength and standing from a chair, adding physical capability to the molecular data.
The Ultra tier expands significantly on this foundation by incorporating intensive clinical imaging. Specialist coverage notes that this higher tier includes additional testing such as brain MRIs and DEXA scans. By stacking these diverse methodologies, the organizers attempt to capture a broader picture of physiological decline, moving beyond single-variable biological age tracking.
The central challenge in evaluating these contest results is that different testing platforms track entirely separate biological processes. While some clocks focus on physical function or specific organs, others are explicitly designed to predict overall mortality. Blood-protein approaches can be highly organ-specific, while other consumer tests use RNA, telomere length, metabolites, or standard vital signs.
These disparate measurements do not all represent the same underlying biological reality. Stanford Medicine explains that DNA-methylation clocks read chemical marks on DNA, but these blood-based epigenetic tests primarily reflect blood cells. They do not directly measure how other organ systems are aging. Therefore, a test that claims to measure systemic aging might only be tracking cellular changes within the bloodstream itself.
The contest report notes that there are currently more than 100 clocks in existence across the longevity research sector. Because there are so many distinct methodologies, these tools likely capture completely different aspects of human aging. Glorioso stated that the contest aims to explain aging clocks and use the resulting data to learn what different clocks actually measure. Those statements reflect the organizer's preliminary goals, rather than proven medical findings that the contest has already established.
Because biological age is not a single standardized measurement, a participant's score can vary wildly depending on the specific organ or metric tested. A single individual might receive completely contradictory results across different testing platforms. Stanford gives the clear example of a person whose cardiovascular measures suggest a younger-than-chronological age while brain-derived proteins indicate a completely different picture.
This precise scenario illustrates why unlike test results do not necessarily mean that one test is simply right and the other is wrong. MIT Technology Review recounts an author receiving a prior result that showed a young heart but a relatively old brain, liver, and hormonal system. These diverging scores highlight the segmented nature of human cellular health, where different bodily systems degrade at highly variable rates.
Translating these conflicting scores into a single cohesive health narrative remains highly problematic for everyday consumers. The contest report describes individual-level interpretation as controversial and quotes the expert assessment that clocks are simply not good enough for that individual application yet. While aggregate population data might show interesting biological trends, isolating a precise biological age for an individual remains mathematically uncertain.
Evaluating biological changes over a strict six-month window introduces significant timing and measurement challenges for both researchers and participants. Stanford researchers caution that changes in human behavior may take several years to appear in an epigenetic blood test. This delayed biological response makes a six-month contest a highly limited window for interpreting any positive or negative score change following new longevity interventions.
Furthermore, the baseline accuracy of the tests themselves can obscure short-term physiological improvements. Stanford's coverage reports that many epigenetic clocks have roughly three years of error built into their mathematical models. If a clock has a three-year margin of error, determining whether a six-month behavioral intervention caused a true biological shift becomes practically impossible without massive sample sizes.
Short-term biological fluctuations can also significantly distort the data recorded on test day. Stanford notes that circulating blood-cell proportions can vary over the course of a single day, which directly complicates the interpretation of an individual epigenetic result. A competitor might show a changed score simply due to the specific time of day they drew their baseline and final blood samples.
Because clocks can have significant measurement error and may respond very slowly to lifestyle interventions, a before-and-after score shift over six months does not definitively prove anything. It would not, by itself, establish that a competitor's overall aging process successfully reversed. The resulting data may offer interesting observational correlations, but it absolutely falls short of proving direct causality.
While the Younger contest serves as a public-facing demonstration of various testing approaches, these commercial tools are not equivalent to rigorous medical diagnostics. Stanford researchers strongly caution against treating consumer biological-age scores as definitive clinical assessments for individual patients. Consumers should actively avoid interpreting a single test result as a formal diagnosis or as a definitive measure of their long-term lifespan.
The regulatory landscape for these testing platforms remains highly restricted in the current clinical environment. Stanford Medicine clearly states that no direct-to-consumer biological-age clocks are FDA-approved medical diagnostic tools in the United States. They lack the extensive clinical validation required to guide formal medical treatment, prescribe therapies, or direct specific disease prevention strategies.
Stanford also points out that biological age, total lifespan, and overall healthspan are related but highly distinct physiological concepts. Researchers are still actively working out the exact biological relationships between these complex variables. Many commercial tests simply lack strong, long-term outcome data to support their most ambitious physiological health claims.
For readers considering purchasing a consumer test, the practical question goes far beyond asking for a single age estimate. Individuals must ask what specific signal the test measures, what the resulting score claims to predict, and exactly how uncertain that prediction truly is. The Stanford explainer specifically cautions that these commercial tests are never appropriate replacements for routine clinical assessment.
The Younger contest functions as a source of preliminary data rather than a rigorous scientific trial, presenting several major limitations:
Future clinical trials must rigorously validate these distinct biological-age clocks across diverse populations to determine exactly which health outcomes each score accurately predicts.
Evaluating what multidimensional biological tests actually measure requires separating valid clinical signals from basic measurement error. AgeAmaze resolves the confusion over conflicting longevity studies, ensuring you can accurately interpret different testing methodologies without turning preliminary scores into definitive medical promises. Read the research
Stay current with research on aging biology, biomarkers, nutrition, therapeutics, peptides and longevity technology. AgeAmaze reports what the evidence shows, where uncertainty remains and which claims still need stronger data.
Follow AgeAmaze for careful reporting on what longevity science can show today and what still needs stronger evidence.
read the Blog
